State of Wyoming’s LAVA Therapeutics LVTX Stock Holding History

State of Wyoming’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-233	Closed	-$816	–	1702
2022 Q4	$816	Buy	+233	New	+$1.07K	﹤0.01%	1516

Other funds holding LVTX

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State of Wyoming's LVTX Position: Q1 2023 in Review

State of Wyoming sold out of LAVA Therapeutics (LVTX) in Q1 2023, closing a stake of 233 shares — an estimated $816 sold.

State of Wyoming first reported a position in LVTX in Q4 2022 and held it in 1 quarter. The position peaked at $816 in Q4 2022. 19 funds tracked by Wall St. Rank hold LVTX as of Q1 2023.

State of Wyoming reported no remaining LAVA Therapeutics position as of Q1 2023 after selling out during the quarter.
State of Wyoming sold 233 LAVA Therapeutics shares in Q1 2023, an estimated $816.
State of Wyoming first reported a position in LAVA Therapeutics in Q4 2022 and held it in 1 quarter.
State of Wyoming's LAVA Therapeutics position peaked at $816 in Q4 2022.
19 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2023.

Based on State of Wyoming's 13F filing for Q1 2023, filed 15 May 2023.